Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01322802 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
A Phase 1 study of Stage IV Ovarian Epithelial Cancer and Stage III Ovarian Epithelial Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01322802 is a Phase 1 study of Stage IV Ovarian Epithelial Cancer and Stage III Ovarian Epithelial Cancer that has completed, run by University of Washington. The registered enrollment target is 25 participants, below the 39-participant average among 4 other Stage IV Ovarian Epithelial Cancer trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01322802, a Phase 1 study of Stage IV Ovarian Epithelial Cancer and Stage III Ovarian Epithelial Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects of vaccine therapy in treating patients with stage III-IV or recurrent ovarian cancer. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-03-06 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01322802
The ClinicalTrials.gov registry entry for NCT01322802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 39-participant average among 4 other Stage IV Ovarian Epithelial Cancer trials with a reported enrollment target (36% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage IV Ovarian Epithelial Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01322802 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01322802 about?
NCT01322802 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer". This phase I trial is studying the side effects of vaccine therapy in treating patients with stage III-IV or recurrent ovarian cancer. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells.
What is the current status of trial NCT01322802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-03-06. Estimated completion is 2020-12-01.
What conditions does trial NCT01322802 study?
This clinical trial studies the following conditions: Stage IV Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Ovarian Germ Cell Tumor.
What interventions are being tested in trial NCT01322802?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01322802?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01322802 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Ovarian Epithelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Stage IV Ovarian Epithelial Cancer
All registered trials for this condition
Stage III Ovarian Epithelial Cancer
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.